User:Mr. Ibrahem/Dalbavancin
From Wikipedia, the free encyclopedia
Dalbavancin, sold under the trade names Dalvance among others, is an antibiotic used to treat bacterial skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).[2] It is give by injection into a vein either as a single dose or two doses one week apart.[2][3]
Clinical data | |
---|---|
Trade names | Dalvance, Xydalba, Zeven, other |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614036 |
License data |
|
Routes of administration | Intravenous |
Legal status | |
Legal status |
|
Identifiers | |
| |
Chemical and physical data | |
Formula | C88H100Cl2N10O28 |
Molar mass | 1816.71 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Common side effects include nausea, diarrhea, rash, and headache.[2] Other side effects may include antibiotic associated colitis, constipation, and low white blood cells.[3] It is unclear if use is safe in pregnancy or breastfeeding.[4] It is in the lipoglycopeptide class of medications, along with vancomycin.[2]
Dalbavancin was approved for medical use in the United States in 2014 and Europe in 2015.[2][5] In the United States the a course of medication costs about 4,800 USD as of 2021.[6] In the United Kingdom this amount costs the NHS about £1,700.[3]